Showing results (251-260 of 288) with videos related to
Sort By:
Pageof 29
Hematological Oncology|August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCLToby A Eyre, Catherine Hildyard, Angela Hamblin, et al.Blood|April 21, 2024
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trialSridhar Chaganti, Shanna Maycock, Graham McIlroy, et al.Journal of Pain and Symptom Management|March 26, 2013
Breakthrough cancer pain: an observational study of 1000 European oncology patientsAndrew Davies, Alison Buchanan, Giovambattista Zeppetella, et al.Nature Communications|May 2, 2023
More than one quarter of Africa's tree cover is found outside areas previously classified as forestFlorian Reiner, Martin Brandt, Xiaoye Tong, et al.Hemasphere|September 25, 2025
Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upCatherine Thieblemont, Maria Gomes Da Silva, Sirpa Leppä, et al.Gut|March 11, 2025
British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancerJervoise Andreyev, Richard Adams, Jan Bornschein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyChulin Sha, Sharon Barrans, Francesco Cucco, et al.Plos One|November 7, 2015
Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor LocusChantal E Hargreaves, Chisako Iriyama, Matthew J J Rose-Zerilli, et al.Blood Advances|November 15, 2023
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experienceRohan Shotton, Rachel Broadbent, Alia Alchawaf, et al.The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.Pageof 29